ISI Group Comments on Gilead Sciences

ISI Group provided color on Gilead Sciences

regarding Gilead Sciences' upcoming earnings announcement tomorrow after market closing. In the report, ISI Group states, "While investors wait for the upcoming QUAD Phase III data readout later this quarter, the focus of the earnings call will probably be on core HIV franchise revenues, particularly around ADAP purchases in the US. Recall that GILD's HIV franchise sales in 1Q11 were lower than consensus in part due to reduced ADAP purchases in Florida and Texas and related inventory work down at the wholesaler level." Shares of Gilead Sciences were trading at $43.17 at the time of posting, down 0.10% from Friday's market close.